Divergent trends in the incidence and mortality of coronary events, especially in women. Evidence from Finland in 1996-2021.

Atte Kallström¹, Ida Holopainen², Oleg Kambur², Markus Perola^{2,3}, Veikko Salomaa², Aki S. Havulinna^{2,4}, Markus Ramste¹*, Juha Sinisalo¹*

Affiliations:

1. Heart and Lung Center, Helsinki University Hospital, University of Helsinki, Helsinki, Finland 2. Finnish Institute for Health and Welfare (THL), Helsinki, Finland. 3. Clinical and Molecular Metabolism Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland 4. Institute for Molecular Medicine Finland, FIMM-HiLIFE, Helsinki, Finland

*Equal contribution

& Correspondence: Juha Sinisalo Heart and Lung Center, Helsinki University Hospital, University of Helsinki, Helsinki, Finland Phone: +35894711

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1 Abstract:

2

3 **Objective:** Acute coronary syndrome (ACS) incidence and case fatality (CF) have declined in the past decades, but some studies have suggested a potential stagnation in this decline. We examined 4 how the ACS burden has evolved among persons aged 35-74 in Finland from 1996 to 2021. 5

6 Methods: We used Finnish country-wide Hospital Discharge- and Causes of Death- Registers covering first non-fatal and fatal ACS events, totaling 69 906 442 person-years at risk. We analyzed 7 incidence, mortality, and 28-day CF, and their trends using negative binomial, Poisson, segmented, 8 9 and logistic regression adjusting for age and sex.

Results: Altogether, the analysis consisted of 186 489 non-fatal and 72 907 fatal ACS events. ACS 10 incidence declined in men (annual percentage change (APC) -2.0% [95% CI -2.2 to -1.8]) and in older 11 women (APC of 55-64 year old -1.5% [-1.7 to -1.2] and 65-74 year old -3.3% [-3.4 to -3.2]), but the 12 13 incidence decline slowed down over the last decade. In younger women aged 35-54, incidence was unchanged during the study period. ACS mortality and CF declined (APC of the mortality in men -14 15 4.4% [-4.6 to -4.2] and in women -5.0% [-5.2 to -4.7]. APC of CF in men -2.7% [-2.8 to -2.6] and in

women -3.3% [-3.6 to -3.1]). 16

Conclusions: ACS mortality declined in all groups, but the decline in ACS incidence slowed down 17 and even halted in women. In women aged 35-54, the incidence was unchanged during the study 18 19 period. These results emphasize the need of intensified cardiovascular prevention, particularly in women. 20

- 21 22 23 24 25 26 27 28 29 30 Key words epidemiology, acute coronary syndrome, incidence, mortality, women 31 32 Key messages 33 34
 - What is already known on this topic During the last decades coronary artery disease • treatment and prevention have improved worldwide which has led to a decline in ACS mortality and case fatality. However, recent studies from several countries suggest, that incidence decline has stagnated or even turned to increase, especially in younger age cohorts.
- What this study adds This study showed that incidence has ceased its decline in women 39 • aged 35-54 and has slowed down in older age groups. Together with declining mortality this 40 results in a growing number of patients living with cardiovascular disease leading to 41 increased healthcare costs. 42
- How this study might affect research, practice, or policy The alarming results of this 43 • study underline the importance of intensifying prevention, focusing especially on young and 44 middle-aged women. 45
- 46

35

36

Introduction 47

48

49 Cardiovascular disease is one of the world's leading causes of death and has been extensively researched ¹². Established modifiable risk factors are hypertension, dyslipidemia, diabetes mellitus, 50 and smoking. Preventive measures that target these risk factors have been shown to be effective and 51 52 have a good cost-benefit ratio³. With these measures, acute coronary syndrome (ACS) mortality rates have declined during the past decades in Western countries. Approximately one-third of total ACS 53 mortality decline is due to an increase in survival after myocardial infarction⁴. Compared to earlier 54 decades, patients now have fewer and less severe symptoms, and survival rates are higher. However, 55 there are worrying signs that these positive trends may not be sustainable, as shown by data from the 56 US and Australia.⁵⁶. It has been proposed that the alarming increases in obesity and diabetes mellitus 57 worldwide are reflected in ACS incidence ⁵⁷. 58

59

In Finland, the coronary heart disease mortality rate has drastically declined during the preceding 60 decades. In the last century from 1960 to 1970 Finland's mortality rate from ACS was among the 61 62 highest in the world. Most of the reduction is due to improving primary and secondary prevention, especially concentrating on the classical cardiovascular risk factors.⁸ Also, a substantial part of the 63 reduction has been gained by advances in the treatment of ACS, including percutaneous coronary 64 intervention and new preventive medications ⁹. Still, the northeastern part of Finland has a 65 substantially higher burden of CHD incidence and mortality, partly due to genetic, environmental, 66 and socioeconomic aspects ^{8 10}. Previous studies have demonstrated that the short-term case fatality 67 and 1-year prognosis of incident MI have improved in both sexes from the mid-1990s to 2002 in 68 Finland¹¹. 69

70

71 Data on trends in ACS incidence and mortality rates, and case fatality during the last years is very sparse all over the world as well as in Finland ⁸¹². As the Finnish electronic health care registries 72 offer reliable and comprehensive nationwide data and a long follow-up period ¹³, we chose to analyze 73 the trends using these registries and compare our findings with available corresponding data from 74 75 other Western countries. We focused on ACS trends in the 35-74 year old population of Finland from 1996 to 2021. We hypothesized that these trends would be declining since ACS mortality in the 76 77 Western world has declined in the past and it was previously projected that age-adjusted ACS event rates would decrease in Finland until 2050¹⁴. 78 79

- 80 Methods
- 81

82 **Study population**

We collected data from Finnish country-wide registers, i.e., hospital discharges, from the Care 83 Register for Health Care and the National Causes of Death Register with complete coverage of non-84 fatal and fatal ACS events, including sudden, out-of-hospital cardiac deaths. A unique personal 85 identification number that every permanent resident in Finland receives at birth or upon immigration 86 87 links the data between the registries. Altogether, the analysis consists of 186 489 non-fatal and 72 907 fatal incident ACS events. 88

89

90 We defined annual population as the population on the last day of each year, available from the Finnish Population Information System. At the end of 2021, the population of Finland aged 35-74 91 was 2.8 million. The study population contributed 69 906 442 person-years at risk. 92

93

The information permit number for the use of the Finnish Cardiovascular Disease Register (CVDR) 94 95 is THL/3624/6.02.00/2023. Permission to access the original data can be applied for through 96 FINDATA.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

97 Definition of ACS events

The data contains only the first non-fatal and fatal ACS events, as previously classified in the WHO-MONICA project ¹⁵. We defined the event as first (i.e., incident) for an individual if he/she had no previous ACS events recorded in the HDR during the preceding 10 years. If a patient had a second ACS event less than 28 days from the onset of the previous event, we considered two events as one and considered only the more severe diagnosis code. We defined an ACS event fatal if the patients died within 28 days from the onset of the event and CF as the proportion of fatal cases of all incident cases.

105

Total ACS events include non-fatal hospitalizations for MI or unstable angina (ICD-9: 410; ICD-10: I20.0, I21-I22), and fatal events, which include deaths with CHD (ICD-9: 410-414; ICD-10: I20-I25),
cardiac arrest (ICD-10: I46), sudden death for unknown reason (Finnish ICD-9: 798, not 7980A; ICD-10: R96), or unwitnessed death (ICD-10: R98) as the underlying or direct cause of death, or deaths with MI (ICD-9: 410; ICD-10: I21-I22) as the contributing cause of death.

111

We assessed ACS incidence, mortality, and case fatality for the entire population of Finland by event age, and by event year and sex. Experimental setup is shown as flowchart in Supplemental Figure 2.

114115 Age groups

We calculated ACS incidence, mortality, and case fatality for the age group 35-74 and further subdivided into smaller age groups as follows 35-44, 45-54, 55-64, and 65-74. CF was an exception since the two youngest age groups were combined into one 35-54 age group to lower the random variation due to low case counts.

120

121 Statistics

We analyzed the incidence and mortality rates, as well as the significance of their trends using Poisson or negative binomial (NB) regression models adjusting for age and sex. We used NB models instead of the Poisson model if there was evidence of overdispersion, and the NB model had a better fit for the given data. We analyzed case fatality trends using the logistic regression model.

126

We used the segmented regression model to analyze the ACS incidence, mortality, and CF trendchanges during the study period.

129

We performed age-standardization of the incidence and mortality rates using the direct method with weights from the 2011-2030 European standard population¹⁶. This standard population allows further comparison with other publications. The weights used for age-standardizing case fatality are based on the age distribution of observed coronary events in MONICA populations in the WHO-MONICA project¹⁵. However, these weights were not defined for older age groups, thus we used weights aimed at a larger age distribution and smaller age groups (Supplemental Table 2).

136

The ACS incidence and mortality rates as well as case-fatality trends are presented in the figures as
three-year moving averages, the first and the last years are counted as two-year averages.

139

We used R version 4.2.2 for all statistical analyses and considered p<0.05 as statistically significant.
All tests were two-tailed. We used package "MASS" (version 7.3-58.1) for negative binomial
regression, "segmented" (version 1.6-2) for segmented regression, and "AER" (version 1.2-10) for
testing whether there was overdispersion in Poisson models. ¹⁷ The code used for the data analysis is
available upon reasonable request.

- 145
- 146
- 147

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

148 Results

149


150 Overall incidence and mortality

In men and women, ACS incidence and mortality declined overall during the study period. (Figure 1). The decline in mortality was markedly steeper than the decline in incidence. The age-standardized ACS mortality rate declined by more than two thirds (in men 65.3% and in women 71.8%) and the incidence rate declined approximately by one third in men (35.1%) and by one quarter in women (24.6%).

156
157 Men have approximately two times higher incidence than women in the oldest age group and four
158 times higher incidence in younger age groups (35-54 year old) (Figure 2A&B). Men have also

approximately three times higher mortality in the oldest age group (65-74 year old) and five times
higher mortality rate in the other age groups (Figure 2C&D). Annual incidence and mortality changes
per age group, number of cases in the age groups, mean age of each group, and p-values of trends can
be seen in Table 1.

- 163
- 164



Incidence --- Mortality --- More Women
 Figure 1: Trends in incidence and mortality rates of ACS in men and women aged 35-75 years, 1996-2021. Rates include
 first non-fatal I20.0, I21, and I22 cases and fatal I20-25, I46, R96 and, R98 cases. Age-standardized rates per 100 000
 inhabitants were calculated with the 2013 European standard population as the reference. Observed incidence and
 mortality rates are presented as dots, the segmented (negative binomial) regression model's predicted values as a line and
 the segmented regression model's 95%-confidence intervals for predictions as a ribbon. The rates are presented on a
 logarithmic scale.

- 172
- 173 174
- 175
- 176
- 177
- 178
- 179
- 180
- 181
- 182

	Mean	Cases	ncidence Average annual change	2724 21	
Age group Men	age	(N)	(%)	95% CI	P-value
All (35-74)*	62.0	185 309	-2.01	-2.20 to -1.82	<10.16
65-74*	69.6	84 763	-2.01 -3.12	-2.20 to -1.82 -3.29 to -2.96	<1e-16 <1e-16
55-64*	59.9	61 912	-2.06	-2.23 to -1.89	<1e-10 <1e-16
45-54*	59.9 50.4	30 985	-2.00	-2.23 to -1.89 -1.57 to -1.22	<1e-10 <1e-16
	40.9	7 649	-1.40		
35-44	40.9	7 649	-1.55	-1.63 to -1.04	<1e-16
Women	647	74.007	1.00	1 02 +- 1 40	(1 - 10
All (35-74)*	64.7	74 087	-1.66	-1.83 to -1.48	<1e-16
65-74*	70.1	44 294	-3.28	-3.40 to -3.16	<1e-16
55-64*	60.2	20 304	-1.46	-1.70 to -1.21	<1e-16
45-54	50.5	7 818	0.20	-0.10 to 0.50	0.19
35-44	41.0	1 671	0.38	-0.25 to 1.02	0.24
		-			
			Mortality		
Men					
All (35-74)*	64.5	56 900	-4.42	-4.59 to -4.24	<1e-16
65-74*	69.6	30 602	-4.49	-4.68 to -4.30	<1e-16
55-64*	60.4	18 028	-4.05	-4.29 to -3.82	<1e-16
45-54	50.8	6 835	-4.77	-5.09 to -4.45	<1e-16
35-44	40.7	1 435	-5.29	-5.98 to -4.60	<1e-16
Women					
All (35-74)*	66.2	16 007	-5.00	-5.21 to -4.72	<1e-16
65-74*	70.1	11 104	-5.50	-5.78 to -5.21	<1e-16
55-64	60.6	3 488	-3.84	-4.28 to -3.39	<1e-16
45-54	50.7	1 104	-4.47	-5.27 to -3.67	<1e-16
35-44	40.9	311	-4.87	-6.36 to -3.40	3.06e-1
		6	se fatality		
Men		- Ca			
All (35-74)	62.0	185 309	-2.71	-2.84 to -2.57	<1e-16
65-74	69.6	84 763	-2.19	-2.37 to -2.01	<1e-16
55-64	59.9	61 912	-2.75	-3.00 to -2.52	<1e-16
35-54	48.5	38 634	-4.45	-4.78 to -4.12	<1e-16
Women		20 00 1			10 10
All (35-74)	64.7	74 087	-3.35	-3.58 to -3.12	<1e-16
65-74	70.1	44 294	-3.35	-3.43 to -2.88	<1e-10 <1e-16
55-64	60.2	20 304	-3.15	-3.28 to -2.30	<1e-10 <1e-16
		20 304	2.15	J.20 10 -2.JU	×TC-T0

F) from 1996 to 238 2021. Incidence and mortality rate trends were analyzed using a Poisson or negative binomial regression model. CF 239 trends were analyzed with a logistic regression model. The rate changes are presented as average annual change percentages during the study period. P-values represent the significance of the trend by study year. 240

241

242 *Negative binomial model was used instead of Poisson model.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Incidence trends 243

The trends in ACS incidence are presented in Figure 2 A) men and B) women. In men, the incidence 244 of ACS declined significantly in all age groups during the study period (annual percentage change 245 (APC) in men -2.0% [95% CI -2.2 to -1.8]) (Table 1). Segmented regression however revealed that 246 the incidence decline has slowed down significantly overall in men and men's age groups 65-74, and 247 55-64 and halted in age group 45-54 from around 2007-2012 onwards (Supplemental Table 1, 248 Supplemental Figures 3&4A). 249

250

In women, the incidence rate declined significantly overall and in the older age groups (overall APC 251 -1.7 [-1.8; -1.5], among 65-74 year old -3.3% [-3.4 to -3.2]) and among 55-64 year old -1.5% [-1.7 to 252 -1.2]). The overall incidence in women did not decline after 2010 and age-specific incidence rates 253 slowed down in the older age groups from 2008-2011 (Supplemental Table 1, Supplemental Figures 254 3&4B). Importantly, in women aged 35-54, ACS incidence stayed the same for over two decades 255 (APC of 35-44 year old 0.4% [-0.3 to 1.0] and 45-54 year old 0.2% [-0.1 to 0.5]). The stagnated or 256 slowed incidence decline is mostly associated with inferior development of non-fatal incident ACS 257 258 events compared to the incidence of all ACS events (Supplemental Figure 1A-C and Supplemental Table 3). The incidence of non-fatal ACS events among young women aged 35-54 has increased 259 during the study period. 260

261






Figure 2: Trends in incidence and mortality rates of ACS in men and women by age group, 1996-2021. A) Incidence 264 rates of men. B) Incidence rates of women. C) Mortality rates of men. D) Mortality rates of women. Incidence rates 265 include first non-fatal I20.0, I21, and I22 and fatal I20-25, I46, R96, and R98 cases. Mortality rates include the fatal cases 266 as mentioned above. Age-standardized rates per 100 000 inhabitants were calculated with the 2011-2030 European 267 standard population as the reference. Observed incidence and mortality rates are presented as dots, the segmented, Poisson

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

or negative binomial regression model's predicted values as a line, and the regression model's 95%-confidence intervals
 for predictions as a ribbon. The rates are presented on a logarithmic scale.

270

271 Mortality trends


- 272 The trends in ACS mortality are presented in Figure 2 C) men and D) women and the breakpoints in
- 273 Supplemental Figure 4C-D. The ACS mortality declined in both sexes and all age groups during the
- study period (APC of the mortality in men 4.4% [-4.6 to -4.2] and in women -5.0% [-5.2 to -4.7]).
- 275 Overall, the annual mortality change was very similar in all age groups. In women, mortality declined
- most in the oldest age group (APC -5.5% [-5.8 to -5.2]) while in men, mortality declined most in the
- 277 youngest age group (APC -5.3% [-6.0 to -4.6]). However, in younger age groups, especially in
- 278 women, case numbers are low (Table 1).
- 279

288

280 **28-day case-fatality trends**

ACS case-fatality declined over the study period in men and women (APC of the CF in men -2.7% [-282 2.8 to -2.6] and in women -3.3% [-3.6 to -3.1]) (Figure 3A). Women exhibited lower ACS case-283 fatality rates across equivalent age groups compared to men (Figure 3B). The decline was not linear, 284 particularly in the older age groups. The case fatality stayed the same or even increased a little from 285 around 2001 to 2010, depending on age group and sex (Supplemental Table 1 and Supplemental 286 Figure 5A&B). The annual decline in case fatality was most significant in the youngest age group,

almost two times faster in women and almost as fast in men compared to the older age groups.



Discussion 289

290

304

313

In this nationwide study of almost 260 000 cases, we found a declining incidence of acute coronary 291 syndrome (ACS) in the population aged 35-74 during the study period of 25 years. In young women 292 aged 35-54, however, the incidence did not decline. Also, in the oldest age groups, the declining 293 294 incidence trends were slowed down during the study period. Furthermore, the overall incidence 295 decline in women halted in the last decade. Other reports have shown that the ACS incidence trend has turned into increase, especially among younger age groups ⁵¹⁸. Our study also showed that the 296 mortality rate declined in men and women and, unlike incidence, in all age groups throughout the 297 study period. The rate of decline was approximately similar in all age groups. The decline in mortality 298 is in line with the earlier prediction ¹⁴. It is also worth noting that the decline in mortality was much 299 faster than in incidence. Case fatality declined similarly to mortality in both men and women and in 300 all age groups during the study period. The decline in case fatality was most significant in the 301 youngest age group which consisted of people aged 35-54 years. The case fatality was overall much 302 lower in women than in men. 303

To understand why the incidence of ACS is no longer steadily declining, we examined the results of 305 the National FinHealth 2017 survey that has gathered information on the health of the Finnish adult 306 population and on the risk factors influencing their health ¹⁹. The FinHealth study showed that the 307 proportion of smokers has declined. The study also showed that the prevalence of elevated LDL has 308 declined, but no changes in low HDL levels were seen. Alcohol abstinence has also increased. 309 310 However, dietary habits have not improved, obesity has increased, as well as the waist-to-hip ratio, and hypertension is still very common in Finland. In summary, except for obesity and diabetes, other 311 ACS-related risk factors have improved. 312

One explanation for the halted incidence decline in women aged 35-54 could be that diabetes is a 314 stronger risk factor in women than in men²⁰, considering that diabetes prevalence has also increased 315 ^{19 21}. Also, even as smoking has lost popularity, tobacco exposure, both current and accumulated, 316 predisposes female smokers to more premature myocardial infarction than men²². Additionally, the 317 use of oral contraceptives, which has increased in popularity in the last decades, could have influenced 318 this negative development. However, the literature regarding their effect on the risk of ischemic heart 319 disease is unanimous ²³⁻²⁵. In addition to these somatic factors, psychosocial factors may play a role. 320 It has been shown that women under 50 years of age who develop a myocardial infarction have more 321 psychosocial risk factors than same-aged men and depressive symptoms have been shown to be 322 associated with chronic heart disease events ²⁶. 323

324

Regarding prevention, studies have shown that primary prevention is implemented even better in 325 women than in men, but women receive less invasive measures and guideline suggested secondary 326 preventive medication than men after myocardial infarction. Although women have a lower risk for 327 recurrent myocardial infarction and lower numbers of 30-day cardiovascular deaths compared to men, 328 329 women are reported to have a higher rate of long-term all-cause mortality.²⁷

330

In the older age groups, the slowing down of the incidence decline may be due to the exhaustion in 331 optimizing preventive treatment and therapeutic inertia, especially when it comes to incorporating 332 new expensive treatment modalities (e.g., PCSK9, siRNA drugs) that will be utilized in younger age 333 groups ²⁸. In addition, for all age groups, improving ACS prevention and reducing mortality beyond 334 optimal treatment of classical risk factors may require a novel avenue of targeting the residual risk²⁹ 335 that may not be related to classical risk factors but mediated through inflammation and other poorly 336 understood pathomechanisms within the vascular wall³⁰. Recently new tools, such as polygenic risk 337 scores, have been developed to predict the residual and genetic risk of ACS³¹. 338

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

A factor that could have an overall influence on the development of incidence and case fatality in the 21st century is the introduction of sensitive troponins to clinical practice, which have the power to detect smaller myocardial infarctions.³². Additionally, the COVID-19 pandemic may have influenced the incidence and mortality figures of the last two years as COVID-19 is a risk factor for acute coronary syndrome ³³.

345

In concordance with other recent reports ^{34 35}, we showed that ACS mortality declined steadily in 346 women and men in all age groups. Awareness of coronary artery disease might influence earlier 347 seeking of care, which results in lower mortality. Because of this favorable trend in mortality, Finland 348 is included in the moderate-risk region in Europe based on the death risk due to cardiovascular 349 disease, leaving still room for improvement as many countries in Western Europe belong to the low-350 risk region ³⁶. Taking this into account, a decline in mortality and incidence could be continuously 351 achieved and improved, especially if the treatment methods evolve and there will be more focus on 352 primary and secondary prevention. 353

354

360

Our results showed that case fatality declined rapidly in men and women, especially in the youngest age group. Finland's positive trend might be explained by the same factors as the decrease in mortality. This can also be influenced by the introduction of sensitive troponins ³². In addition, we identified a plateau phase in the overall declining case fatality trend from 2002 to 2010. An explanation for this plateau phase in CF is not known.

Our study is based on comprehensive nationwide Finnish Cardiovascular Disease Register data which 361 covers all symptomatic acute coronary syndrome incidents in Finland with a long study period of 362 twenty-five years. However, the study should be interpreted with certain limitations in mind: the 363 364 underlying Finnish health care registers do not provide individual information for example ECGs or troponin levels, thus the diagnoses of the cases cannot be further verified. Additionally, silent 365 myocardial infarctions are not found in the registers. However, cardiovascular diagnoses in Finnish 366 healthcare registers have been validated and found reliable which increases the confidence in our 367 results ¹³. 368

369

370 Conclusions

371

372 Our study demonstrated diverging trends in different components of ACS event rates in the Finnish population aged 35-74 years. The ACS mortality and CF are steeply declining, whereas the incidence 373 decline is leveling off. Notably, the decline in incidence in older age groups has slowed during the 374 last decade. Also, the overall incidence in women ceased to decline. Indirectly, this may result in an 375 increase in CAD patients in the Finnish population. Consequently, the need for treatment, secondary 376 prevention, and rehabilitation resources is likely to increase as well. Particularly alarming is the halted 377 incidence decline in women aged 35-54 years. Since the incidence of first events can be reduced by 378 primary prevention only, this emphasizes the importance of improving the primary prevention 379 measures, focusing especially on young and middle-aged women. 380

- 381
- 382 Author contributions
- 383

A.K., M.R., V.S., A.H. and J.S. wrote the manuscript. M.P., A.H., M.R, V.S., and J.S. designed the
research. A.K., M.R., V.S., A.H. and J.S. performed the research. A.K., I.H., O.K. and A.H. analyzed
the data.

- 387
- 388 Acknowledgement
- 389

The authors wish to acknowledge CSC – IT Center for Science, Finland, for computational resources. 390 391 392 **Funding information** 393 M.R. received support from Sigrid Juselius Foundation, Emil Aaltonen Foundation, Biomedicum 394 Helsinki Foundation, Orion Research Foundation, and from Finnish Foundation for Cardiovascular 395 Research. V.S. was supported by the Juho Vainio Foundation. I.H. was supported by Aarne Koskelo 396 Foundation and Otto A. Malm Foundation. 397 398 399 **Conflict of Interest** 400 V.S. has had a research collaboration with Bayer Ltd (outside the present study). 401 402 403 404 405 References: 406 1. Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of 407 cardiovascular disease: a historical perspective. Lancet 2014;383(9921):999-1008. doi: 408 409 10.1016/s0140-6736(13)61752-3 [published Online First: 20130929] 410 2. Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 411 1990–2019. Journal of the American College of Cardiology 2020;76(25):2982-3021. doi: 412 doi:10.1016/j.jacc.2020.11.010 3. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in 413 clinical practice. Eur Heart J 2021;42(34):3227-337. doi: 10.1093/eurheartj/ehab484 414 415 4. Mensah GA, Wei GS, Sorlie PD, et al. Decline in Cardiovascular Mortality: Possible Causes and Implications. Circ Res 2017;120(2):366-80. doi: 10.1161/circresaha.116.309115 416 417 5. Ma J, Ward EM, Siegel RL, Jemal A. Temporal Trends in Mortality in the United States, 1969-2013. JAMA 2015;314(16):1731-39. doi: 10.1001/jama.2015.12319 418 6. O'Flaherty M, Allender S, Taylor R, et al. The decline in coronary heart disease mortality is slowing in 419 420 young adults (Australia 1976-2006): a time trend analysis. Int J Cardiol 2012;158(2):193-8. doi: 421 10.1016/j.ijcard.2011.01.016 [published Online First: 20110202] 422 7. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity 423 in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease 424 Study 2013. Lancet 2014;384(9945):766-81. doi: 10.1016/s0140-6736(14)60460-8 [published Online 425 First: 20140529] 426 8. Jousilahti P, Laatikainen T, Peltonen M, et al. Primary prevention and risk factor reduction in coronary 427 heart disease mortality among working aged men and women in eastern Finland over 40 years: population based observational study. Bmj 2016;352:i721. doi: 10.1136/bmj.i721 [published Online 428 429 First: 20160301] 9. Laatikainen T, Critchley J, Vartiainen E, et al. Explaining the decline in coronary heart disease mortality in 430 Finland between 1982 and 1997. Am J Epidemiol 2005;162(8):764-73. doi: 10.1093/aje/kwi274 431 432 [published Online First: 20050908] 10. Havulinna AS, Pääkkönen R, Karvonen M, Salomaa V. Geographic patterns of incidence of ischemic 433 434 stroke and acute myocardial infarction in Finland during 1991-2003. Ann Epidemiol 2008;18(3):206-435 13. doi: 10.1016/j.annepidem.2007.10.008 11. Lehto HR, Lehto S, Havulinna AS, et al. Sex differences in short- and long-term case-fatality of myocardial 436 437 infarction. Eur J Epidemiol 2011;26(11):851-61. doi: 10.1007/s10654-011-9601-6 [published Online First: 20110630] 438

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

439 12. Dégano IR, Salomaa V, Veronesi G, et al. Twenty-five-year trends in myocardial infarction attack and 440 mortality rates, and case-fatality, in six European populations. Heart 2015;101(17):1413-21. doi: 441 10.1136/heartjnl-2014-307310 [published Online First: 20150408] 442 13. Pajunen P, Koukkunen H, Ketonen M, et al. The validity of the Finnish Hospital Discharge Register and 443 Causes of Death Register data on coronary heart disease. Eur J Cardiovasc Prev Rehabil 444 2005;12(2):132-7. doi: 10.1097/00149831-200504000-00007 445 14. Salomaa V, Havulinna AS, Koukkunen H, et al. Aging of the population may not lead to an increase in the numbers of acute coronary events: a community surveillance study and modelled forecast of the 446 447 future. Heart 2013;99(13):954-59. doi: 10.1136/heartjnl-2012-303216 448 15. M. Mähönen HT-P, A. Rajakangas, Z. Cepaitis, K. Kuulasmaa, A. Dobson and U. Keil. Definitions of case 449 fatality for coronary events in the WHO MONICA Project. 2000 doi: 450 https://www.thl.fi/publications/monica/carpfish/appendd/cfdef.htm 451 16. Institute NC. Standard Population Data 2012 [cited 2023. Available from: 452 https://seer.cancer.gov/stdpopulations/stdpop.19ages.html. 453 17. R: A language and enviromental for statistical computing [program]: R Foundation for Statistical 454 Computing, 2022. 18. Gabet A, Danchin N, Juillière Y, Olié V. Acute coronary syndrome in women: rising hospitalizations in 455 456 middle-aged French women, 2004-14. Eur Heart J 2017;38(14):1060-65. doi: 457 10.1093/eurheartj/ehx097 19. P. Koponen, K. Borodulin, A. Lundqvist, et al. Terveys, toimintakyky ja hyvinvointi Suomessa, FinTerveys 458 459 2017 -tutkimus, 2017. 460 20. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in 461 men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006;332(7533):73-78. doi: 462 10.1136/bmj.38678.389583.7C 463 21. M. Arffman, P. Ilanne-Parikka, I. Keskimäki, et al. Tyypin 1 ja 2 diabeteksen ja niiden lisäsairauksien 464 ilmaantuvuus ja esiintyvyys Suomessa vuosina 2000–2017. 2020 doi: 465 https://www.julkari.fi/bitstream/handle/10024/139885/URN ISBN 978-952-343-501-8.pdf?sequence=1&isAllowed=y 466 467 22. Grundtvig M, Hagen TP, German M, Reikvam A. Sex-based differences in premature first myocardial 468 infarction caused by smoking: twice as many years lost by women as by men. Eur J Cardiovasc Prev 469 Rehabil 2009;16(2):174-9. doi: 10.1097/HJR.0b013e328325d7f0 470 23. Okoth K, Chandan JS, Marshall T, et al. Association between the reproductive health of young women and cardiovascular disease in later life: umbrella review. Bmj 2020;371:m3502. doi: 471 472 10.1136/bmj.m3502 [published Online First: 20201007] 473 24. Barsky L, Shufelt C, Lauzon M, et al. Prior Oral Contraceptive Use and Longer Term Mortality Outcomes 474 in Women with Suspected Ischemic Heart Disease. J Womens Health (Larchmt) 2021;30(3):377-84. 475 doi: 10.1089/jwh.2020.8743 [published Online First: 20210121] 25. Bassuk SS, Manson JE. Oral contraceptives and menopausal hormone therapy: relative and attributable 476 477 risks of cardiovascular disease, cancer, and other health outcomes. Ann Epidemiol 2015;25(3):193-478 200. doi: 10.1016/j.annepidem.2014.11.004 [published Online First: 20141113] 479 26. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with 480 myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364(9438):937-52. doi: 10.1016/s0140-6736(04)17018-9 481 482 27. DeFilippis EM, Collins BL, Singh A, et al. Women who experience a myocardial infarction at a young age 483 have worse outcomes compared with men: the Mass General Brigham YOUNG-MI registry. 484 European Heart Journal 2020;41(42):4127-37. doi: 10.1093/eurheartj/ehaa662 485 28. Dixon DL, Sharma G, Sandesara PB, et al. Therapeutic Inertia in Cardiovascular Disease Prevention: Time to Move the Bar. J Am Coll Cardiol 2019;74(13):1728-31. doi: 10.1016/j.jacc.2019.08.014 486 487 29. Toso A, Leoncini M, Maioli M, et al. Residual risk after acute coronary syndrome: the PRATO-ACS 488 Registry. European Heart Journal 2021;42(Supplement_1) doi: 10.1093/eurheartj/ehab724.2466

30. Del Buono MG, Montone RA, lannaccone G, et al. Redefining residual inflammatory risk after acute coronary syndrome. Future Cardiol 2022;18(2):115-23. doi: 10.2217/fca-2021-0032 [published Online First: 20210816] 31. Klarin D, Natarajan P. Clinical utility of polygenic risk scores for coronary artery disease. Nat Rev Cardiol 2022;19(5):291-301. doi: 10.1038/s41569-021-00638-w [published Online First: 20211122] 32. Salomaa V, Ketonen M, Koukkunen H, et al. The effect of correcting for troponins on trends in coronary heart disease events in Finland during 1993–2002: the FINAMI study. European Heart Journal 2006;27(20):2394-99. doi: 10.1093/eurheartj/ehl120 33. Katsoularis I, Fonseca-Rodríguez O, Farrington P, et al. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. Lancet 2021;398(10300):599-607. doi: 10.1016/s0140-6736(21)00896-5 [published Online First: 20210729] 34. Neumann JT, Goßling A, Sörensen NA, et al. Temporal trends in incidence and outcome of acute coronary syndrome. Clinical Research in Cardiology 2020;109(9):1186-92. doi: 10.1007/s00392-020-01612-1 35. Zuin M, Rigatelli G, Temporelli P, et al. Trends in acute myocardial infarction mortality in the European Union, 2012–2020. European Journal of Preventive Cardiology 2023;30(16):1758-71. doi: 10.1093/eurjpc/zwad214 36. SCORE2 wg risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. European Heart Journal 2021;42(25):2439-54. doi: 10.1093/eurheartj/ehab309

Supplemental Material 530

531 Supplemental Table 1: Segmented (Poisson or negative binomial) regression model's breakpoints and intervals of 532 incidence, mortality, and case fatality trends. Intervals where there was no trend change are shown on a yellow 533 background and increasing trends are shown on a red background.

	Incidence				
Age group	Breakpoints	Interval 1 (estimate + slope [95% CI])	Interval 2 (estimate + slope [95% CI])	Interval 3 (estimate + slope [95% CI])	
Men					
All (35-74)	2003, 2009	-10.398 - 0.009 [-0.020; 0.002] * year	-10.175 - 0.039 [-0.062; -0.017] * year	-10.521 - 0.013 [-0.018; -0.007] * year	
65-74	2002, 2012	-8.383 - 0.018 [-0.029; -0.007] * year	-8.215 - 0.045 [-0.053; -0.038] * year	-8.636 - 0.018 [-0.025; -0.012] * year	
55-64	2004, 2007	-8.880 - 0.018 [-0.027; -0.009] * year	-8.662 - 0.047 [-0.073; -0.020] * year	-9.045 - 0.013 [-0.017; -0.009] * year	
45-54	2003, 2009	-10.924 - 0.006 [-0.004; 0.017] * year	-10.626 - 0.037 [-0.049, -0.027] * year	-11.052 - 0.005 [-0.010; 0.000] * year	
35-44	2001	-13.973 + 0.010 [-0.015; 0.034] * year	-13.840 - 0.017 [-0.021; -0.012] * year	-	
Women					
All (35-74)	2001, 2011	-12.619 + 0.012 [-0.004; 0.028] * year	-12.367 - 0.035 [-0.043; -0.026] * year	-12.810 - 0.004 [-0.011; 0.003] * year	
65-74	2001, 2011	-11.582 - 0.008 [-0.022; 0.006] * year	-11.360 - 0.051 [-0.059; -0.043] * year	-11.888 - 0.015 [-0.021; -0.011] * year	
55-64	2004, 2008	-12.083 + 0.001 [-0.010; 0.011] * year	-11.567 - 0.064 [-0.120; -0.008] * year	-12.315 - 0.001 [-0.007; 0.004] * year	
45-54	2001, 2016	-13.431 + 0.060 [0.024; 0.097] * year	-13.121 - 0.009 [-0.015; -0.002] * year	-13.881 + 0.029 [-0.007; 0.066] * year	
35-44	2000	-16.447 + 0.069 [-0.009; 0.147] * year	-16.132 - 0.003 [-0.011; 0.006] * year	-	

Mortality				
Men				
All (35-74)	2020	-12.377 - 0.046 [-0.048; -0.044] * year	-13.618 + 0.007 [-0.101; 0.114] * year	
65-74	2005, 2020	-10.349 - 0.060 [-0.068; -0.051] * year	-10.504 - 0.042 [-0.046; -0.037] * year	-12.784 + 0.054 [-0.050; 0.016] * year
55-64	2001, 2010	-11.605 - 0.055 [-0.075; -0.036] * year	-11.720 - 0.032 [-0.043; -0.021] * year	-11.477 - 0.049 [-0.058; -0.040] * year
45-54	2005, 2014	-13.462 - 0.033 [-0.046; -0.020] * year	-13.170 - 0.067 [-0.083; -0.050] * year	-13.895 - 0.027 [-0.052; -0.001] * year
35-44	-	-	-	-
Women				
All (35-74)	2006	-15.091 - 0.061 [-0.069; -0.053] * year	-15.258 - 0.044 [-0.050; -0.038] * year	-
65-74	2006	-14.738 - 0.079 [-0.088; -0.069] * year	-15.106 - 0.042 [-0.049; -0.035] * year	
55-64	-			-
45-54	2003, 2020	-14.752 - 0.001 [-0.049; 0.046] * year	-14.320 - 0.065 [-0.082; -0.048] * year	-26.779 + 0.456 [-0.136; 1.048] * year
35-44	2011	-15.841 - 0.025 [-0.055; 0.005] * year	-14.442 - 0.119 [-0.192; 0.045] * year	-

Case fatality

Men				
All (35-74)	2002, 2010	-2.557 - 0.060 [-0.069, -0.052] * year	-2.908 - 0.006 [-0.013, 0.002] * year	-2.473 - 0.036 [-0.041, -0.031] * year
65-74	2004, 2010	-2.059 - 0.061 [-0.070, -0.053] * year	-2.746 + 0.020 [0.002, 0.038] * year	-2.088 - 0.027 [-0.034, -0.020] * year
55-64	2001, 2010	-2.917 - 0.062 [-0.083, -0.042] * year	-3.228 - 0.000 [-0.013, 0.013] * year	-2.561 - 0.049 [-0.057, -0.041] * year
35-54	-	-	-	-
Women				
All (35-74)	2004, 2009	-2.881 - 0.075 [-0.088, -0.063] * year	-3.491 + 0.004 [-0.017, 0.026] * year	-2.959 - 0.036 [-0.045, -0.028] * year
65-74	2004, 2010	-3.380 - 0.085 [-0.099, -0.070] * year	-4.142 + 0.012 [-0.016, 0.04] * year	-3.582 - 0.029 [-0.040, -0.019] * year
55-64	2012	-3.724 - 0.021 [-0.030, -0.012] * year	-3.244 - 0.050 [-0.077, -0.023] * year	-
35-54	-	-	-	-

534 Supplemental Table 2: The weights for age-standardizing case fatality. Based on the age distribution of observed 535 coronary events in MNICA populations in the WHO-MONICA project.

Age (years)	Weights
0-4	1
5-9	1
10-14	1
15-19	1
20-24	1
25-29	1
30-34	2
35-39	5
40-44	9
45-49	16
50-54	26
55-59	42
60-64	56
65-69	75
70-74	93
75-79	100
80-84	100
85-	100


536

537 Supplemental Table 3: Average annual changes in acute coronary syndrome non-fatal incident incidence from 1996 to 2021. Incidence rate trends were analyzed using a Poisson or negative binomial regression model. The rate changes are 538 539 presented as average annual change percentages during the study period. P-values represent the significance of the trend 540 by study year.

Incidence				
Age group	Average annual change (%)	95% CI	P-value	
Men				
All (35-74)*	-1.16	-1.37 to -0.95	5.70e-27	
65-74*	-2.35	-2.55 to -2.16	3.56e-123	
55-64*	-1.25	-1.44 to -1.06	1.09e-35	
45-54*	-0.47	-0.67 to -0.26	6.26e-6	
35-44	-0.44	-0.77 to -0.12	0.008	
Women				
All (35-74)*	-0.92	-1.11 to -0.71	1.16e-18	
65-74*	-2.48	-2.69 to -2.27	6.27e-117	
55-64*	-0.97	-1.24 to -0.71	1.36e-12	
45-54	0.96	0.64 to 1.29	5.65e-9	
35-44	1.57	0.86 to 2.29	1.35e-5	


541 *Negative binomial model was used instead of Poisson model.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Supplemental Figure 1: Trends in incidence of first non-fatal ACS incidents in men and women by age group, 1996-2021. A. Incidence rates of men and women aged 35-74. B. Incidence rates of men in 10-year age groups. C. Incidence rates of women in 10-year age groups. Incidence rates include first non-fatal I20.0, I21, and I22 cases. Agestandardized incidence rates per 100 000 inhabitants were calculated with the 2011-2030 European standard population as the reference. Observed incidences are presented as dots, the segmented (Poisson or negative binomial) regression model predicted values as a line and the segmented regression model 95%confidence intervals for predictions as a ribbon. The rates are presented on a logarithmic scale.

- 542
- 543
- 544
- 545
- 546
- 547
- 548
- 549



for Health Care and the National Causes of Death Register.

> Died within 28 days from the onset of the event

72 907 fatal incidents


550

551 **Supplemental Figure 2:** Flowchart of the study population and methods.

Incidence and mortality rates, and the significance of their trends analyzed with Poisson and negative binomial regression models. Case fatality analyzed with logistics regression model. Trend changes further analyzed with segmented regression model.

186 489 non-fatal incidents

- 552
- 553




554

Supplemental Figure 3: Trends in incidence and mortality rates of acute coronary syndrome in men and women aged
35-75 years, 1996-2021. Rates include first non-fatal I20.0, I21, and I22 cases and fatal I20-25, I46, R96 and, R98
cases. Age-standardized rates per 100 000 inhabitants were calculated with the 2013 European standard population as
the reference. Observed incidence and mortality rates are presented as dots, the segmented (negative binomial)
regression model's predicted values as a line, and the regression model's 95%-confidence intervals for predictions as a
ribbon. Breakpoints where there is significant trend change are marked as vertical dashed lines. The rates are presented
on a logarithmic scale.

medRxiv preprint doi: https://doi.org/10.1101/2023.12.01.23299126; this version posted December 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .






563



565 Supplemental Figure 4: Trends in incidence and mortality rates of acute coronary syndrome in men and women by age 566 group, 1996-2021. A) Incidence rates of men, and B) women. C) Mortality rates of men, and D) women. Incidence rates 567 include first non-fatal I20.0, I21, and I22 and fatal I20-25, I46, R96, and R98 cases. Mortality rates include the fatal cases 568 as mentioned above. Age-standardized rates per 100 000 inhabitants were calculated with the 2011-2030 European 569 standard population as the reference. Observed incidence and mortality rates are presented as dots, the segmented, Poisson 570 or negative regression model's predicted values as a line, and the regression model's 95%-confidence intervals for 571 predictions as a ribbon. Breakpoints where there is significant trend change are marked as vertical dashed lines. The rates 572 are presented on a logarithmic scale.





575

576 Supplemental Figure 5: Trends in case fatality (CF) of acute coronary syndrome A) among men and women aged 35-577 74, and B) by 10-year age groups, 1996-2021. CF includes the first non-fatal I20.0, I21, and I22 and fatal I20-25, I46, 578 R96, and R98 cases. CF was age-standardized using weights based on the age distribution of observed coronary events 579 in populations participating in the WHO-MONICA project. Observed case-fatality is presented as dots, the segmented 580 or logistic regression model's predicted values as a line, and the regression model's 95%-confidence intervals for 581 predictions as a ribbon. Breakpoints where there is significant trend change are marked as vertical dashed lines.